Question · asked by 1 review
Radioisotopes vs placebo: Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute
- Population
- patients with metastatic bone pain
- Intervention
- Radioisotopes
- Comparison
- placebo
- Outcome
- Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute
Radioisotopes showed no clear difference in thrombocytopenia III‐IV compared with placebo (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Radioisotopes vs Placebo Thrombocytopenia III‐IV · patients with metastatic bone pain Radioisotopes showed no clear difference in thrombocytopenia III‐IV compared with placebo (low certainty). Radioisotopes for metastatic bone pain (2011) · Cochrane Headline outcomes only | RR 2.21 [0.98, 4.99] | 4 studies · 313 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Radioisotopes for metastatic bone pain 2011 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.